Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday

Key Points

• Prothena is expected to announce its Q2 2025 earnings on August 4th, with analysts predicting an earnings loss of ($1.06) per share and revenue of $5.36 million.
• The company's last quarterly results showed a revenue of $2.83 million, significantly below the expected $8.18 million, alongside a negative net margin of 79.94%.
• Analysts have varied opinions on Prothena, with recent price target adjustments suggesting a decline, bringing the average target price down to $31.50 from previous levels.

Prothena (NASDAQ:PRTA - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Monday, August 4th. Analysts expect Prothena to post earnings of ($1.06) per share and revenue of $5.36 million for the quarter.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). The firm had revenue of $2.83 million for the quarter, compared to analysts' expectations of $8.18 million. Prothena had a negative net margin of 79.94% and a negative return on equity of 21.61%. The company's quarterly revenue was up 5500.0% on a year-over-year basis. During the same period in the previous year, the company earned ($1.34) EPS. On average, analysts expect Prothena to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Prothena Price Performance

PRTA traded down $0.06 during trading on Friday, hitting $6.81. 840,982 shares of the stock traded hands, compared to its average volume of 765,312. The firm has a market capitalization of $366.56 million, a P/E ratio of -3.27 and a beta of -0.03. The firm has a 50-day moving average of $5.95 and a 200 day moving average of $9.88. Prothena has a 12-month low of $4.32 and a 12-month high of $23.66.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PRTA. Cantor Fitzgerald reissued a "neutral" rating on shares of Prothena in a research report on Friday, June 20th. Jefferies Financial Group cut shares of Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target for the company. in a research report on Tuesday, May 27th. Piper Sandler dropped their target price on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday, May 27th. Oppenheimer cut shares of Prothena from an "outperform" rating to a "market perform" rating in a research report on Tuesday, May 27th. Finally, JMP Securities dropped their target price on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research report on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Prothena presently has a consensus rating of "Hold" and a consensus target price of $31.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Prothena stock. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 18,553 shares of the biotechnology company's stock, valued at approximately $230,000. 97.08% of the stock is owned by hedge funds and other institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.